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Abstract
The molecular genetic relationship between esophageal adenocarcinoma (EAC) and its precursor 
lesion, Barrett’s esophagus, is poorly understood. Using whole-genome sequencing on 23 paired 
Barrett’s esophagus and EAC samples, together with one in-depth Barrett’s esophagus case-study 
sampled over time and space, we have provided new insights on the following aspects: i) Barrett’s 
esophagus is polyclonal and highly mutated even in the absence of dysplasia; ii) when cancer 
develops, copy number increases and heterogeneity persists such that the spectrum of mutations 
often shows surprisingly little overlap between EAC and adjacent Barrett’s esophagus; and iii) 
despite differences in specific coding mutations the mutational context suggests a common 
Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, 
subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
Correspondence: Professor R C Fitzgerald FMedSci, MRC Cancer Unit, Hutchison/MRC Research Centre, Hills Road, Cambridge, 
CB2 0XZ, UK, rcf29@mrc-cu.cam.ac.uk, Tel: +44 (0)1223 763287, Fax: +44 (0)1223 763241.
5A full list of members and affiliations appears at the end of the paper
Author contributions
RCF conceived the overall study and takes responsibility for the data integrity. CSRI, JB and RKC analyzed the data. CSRI extracted 
the AHM1051 samples. AW developed the targeted sequencing data visualization tool. CSRI, JB, RKC, HN, JMJW, MR, SH, DB, 
RCF designed various aspects of the study. HN performed the TSCA assay. CSRI, JB and AGL performed the statistical analysis. 
MdP collected endoscopic samples for patient AHM1051. MO’D and SM performed the histopathological diagnosis. SI developed the 
copy number pipeline and RKC and MH performed the copy number analysis. ZK ran the WGS of patient AHM1051. RCF, SH, DB, 
MR supervised the study. CSRI, JB, RKC and RCF wrote the manuscript. All authors approved the final version of the manuscript.
Accession codes
WGS data can be found at EGAD00001001394. Supplementary table 4 provides the information to match the sample identifiers to the 
patients presented in this manuscript.
COMPETING FINANCIAL INTERESTS
RCF developed the Cytosponge technology which has been licensed by MRC-Technology to Covidien. RCF has no direct pecuniary 
interest. JB, AW, RKC, HN, SI, MH, ZK, MR, SH, DB are employees of Illumina.
Europe PMC Funders Group
Author Manuscript
Nat Genet. Author manuscript; available in PMC 2016 March 01.
Published in final edited form as:
Nat Genet. 2015 September ; 47(9): 1038–1046. doi:10.1038/ng.3357.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
causative insult underlying these two conditions. From a clinical perspective, the histopathological 
assessment of dysplasia appears to be a poor reflection of the molecular disarray within the 
Barrett’s epithelium and a molecular Cytosponge™ technique overcomes sampling bias and has 
capacity to reflect the entire clonal architecture.
Introduction
Most epithelial cancers present de novo but have progressed from a clinically silent pre-
invasive state or so-called intra-epithelial neoplasia. There is growing interest in 
understanding the life-history of cancers at a molecular level1 so that more focused cancer 
prevention strategies can be implemented which circumvent the current problems of over-
diagnosis inherent in mass screening programs2. Barrett’s esophagus is the precursor lesion 
to the aggressive cancer, esophageal adenocarcinoma (EAC). In a minority of patients, 
estimated at 0.33% per year3, Barrett’s esophagus can progress from non-dysplastic 
Barrett’s esophagus, through intermediate stages of low-grade dysplasia (LGD) and high-
grade dysplasia (HGD) to adenocarcinoma. This condition is a classic example of a disease 
in which clinical strategies characterized by endoscopic random biopsy sampling and 
pathological diagnosis have arguably failed to improve outcomes for patients4,5.
Historically studies have focused on mutation, methylation and/or loss of heterozygosity of 
specific target genes, most commonly p16 and TP53, to try to understand the natural history 
of Barrett’s esophagus and to predict patients at high-risk of cancer6-10. However, there are 
conflicting interpretations of these data concerning the clonal evolution of this disease. One 
model formulated by Maley and colleagues7,11 proposed that a mutation (most commonly 
inactivation of p16), that confers a selective advantage to a cell will sweep across the 
Barrett’s segment resulting in this mutation being present in the majority of the cells in that 
Barrett’s segment, a so-called selective sweep. As additional advantageous mutations arise 
(commonly TP53 loss), these cell clones can then also expand across the Barrett’s segment. 
This results in a cancer with a serial accumulation of mutations, including drivers and 
hitchhikers, a proportion of which would be present in all Barrett’s epithelium. Leedham et 
al.6 have subsequently described a more heterogeneous model whereby multiple 
independent clones arise, some of which die out, and some of which are maintained. Hence, 
genetic aberrations present within these clones would not necessarily sweep across the 
whole Barrett’s segment, depending on the competitive advantage of the individual clones. 
This scenario could lead to a far more heterogeneous Barrett’s esophagus and cancer tissue. 
Although the two different models are not mutually exclusive12, the limited resolution of the 
molecular genetic alterations that stems from analysis of a small number of candidate genes, 
has made it difficult to resolve the issue.
Recent DNA sequencing studies have demonstrated a high mutational burden within 
EAC13-16, and described distinct mutational signatures observed within this cancer 
type13,16,17. TP53 is by far the most commonly mutated gene within EAC, followed by a 
plethora of genes that are mutated in a smaller proportion of cases (<25%), such as ARID1A, 
SMARCA4, SMAD4 and SYNE115,16. In a study using exome sequencing data from two 
matched Barrett’s and EAC samples, Agrawal and colleagues14 found that approximately 
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80% of the cancer mutations were already present in DNA from the adjacent Barrett’s 
epithelium. However, the grade of dysplasia and the spatial relationship of these samples 
were not reported. We recently demonstrated that putative esophageal driver genes, such as 
ARID1A and SMARCA4, were also recurrently mutated in patients with a very stable 
phenotype who had never shown any evidence of dysplasia within their Barrett’s segment 
over multiple years of follow-up (median 58 months)13. This would argue against such 
genes having a causal role in cancer progression. In contrast, TP53 and SMAD4 mutations 
were highly specific to patients with HGD and EAC, respectively. However, though 
informative, these studies were not designed to deduce the clonal architecture over time and 
space for Barrett’s esophagus carcinogenesis.
The aims of this study were therefore to examine the clonal ordering and heterogeneity of 
Barrett’s esophagus (including various degrees of dysplasia) that had progressed to EAC. 
We were able to examine this to a higher level of detail than had been previously possible 
through virtue of some highly characterized sample-sets and the recent technological 
developments which permit genome-wide sequencing from minute pieces of paraffin-
embedded archival material, as well as fresh-frozen tissues. Thus we interrogated the 
mutational landscape, on a genome-wide scale, of 23 paired Barrett’s esophagus and EAC 
samples as well as 73 samples taken over a three-year period from one patient’s Barrett’s 
esophagussegment (displaying all the different stages of progression, from non-dysplastic 
Barrett’s to intramucosal adenocarcinoma). From these data we were able to determine the 
mutational load, the mutational context as well as the clonal composition and heterogeneity 
in pathologically defined steps of Barrett’s esophagus carcinogenesis.
Results
Barrett’s esophagus is highly mutated and polyclonal
Paired Barrett’s and cancer samples taken at the same time point from 23 EAC patients (see 
Supplementary Table 1 and 2 for demographic and tumor information) with macroscopically 
visible Barrett’s esophagus were whole-genome sequenced. All Barrett’s and EAC samples 
were sequenced to a minimum of 54-fold coverage and the germline normal comparison 
(blood or normal esophageal squamous) to a minimum of 31-fold coverage (Supplementary 
Table 3). The median number of single nucleotide variants (SNVs) present within the EAC 
samples was 18,786 (interquartile range (IQR) 15,007-32,034) and 12,714 (IQR 
6,604-21,559) for the Barrett’s esophagus samples. The average somatic mutation rate for 
the Barrett’s samples was 6.76/Mb which is higher than for multiple myeloma (2.9 
SNVs/Mb)18, luminal breast cancer (1.1 SNVs/Mb)19, hepatocellular carcinoma (3.69 
SNVs/Mb)20 and colorectal adenocarcinoma (5.9 SNVs/Mb)21. Although Barrett’s 
esophagus adjacent to EAC was found to be highly mutated and contain thousands of SNVs, 
even for samples with no histological dysplasia, there were significantly more SNVs called 
in the tumor samples (average somatic mutation rate 10.02/Mb) compared to the Barrett’s 
esophagus samples, (Wilcoxon Signed Rank test, p<0.001)(Figure 1a). Furthermore, this 
was apparently not driven by a difference in the purity between the Barrett’s and the tumor 
samples as there was no significant correlation between the number of SNVs called and the 
purity of the samples (Spearman’s Rho, r=0.108, p=0.475) (Supplementary Table 3). Of 
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note, the Barrett’s esophagus samples with dysplasia (either LGD, HGD or indefinite for 
dysplasia called by two independent expert pathologists), did not have significantly more 
mutations than the Barrett’s esophagus samples with no dysplasia (Mann Whitney test, 
p=0.271).
Surprisingly, when we looked at the percentage of SNVs that were common to both the 
paired Barrett’s esophagus and EAC samples, after performing additional filtering and only 
considering SNVs with good coverage in both paired samples (see online methods for more 
information), we found a lower degree of overlap than we would have first expected (<20% 
overlap between the SNVs in the paired Barrett’s esophagus and the EAC samples in 13/23 
(57%) of the samples), and this low degree of overlap was not primarily due to loss of 
heterozygosity (LOH) in the paired sample (Figure 1b) or differences in purity or 
sequencing depth between the paired samples. The Barrett’s esophagus samples that had a 
better overlap with their paired EAC sample were more likely to be dysplastic (Mann-
Whitney test, p=0.019). We did not find any other association between samples with a poor 
overlap and any clinical features, such as stage or differentiation status of the tumor, age or 
gender of the patient as well as the length of the Barrett’s segment or the tumor (p>0.5 for 
all comparisons). As expected TP53 was the most recurrently-mutated gene occurring in 
19/23 (82.6%) EAC samples. Barrett’s esophagus samples harbored TP53 mutations less 
commonly (9/23 (39.1%) of which 5 were dysplastic). Of note, TP53 mutations present 
within Barrett’s esophagus adjacent to EAC were not always present within the paired EAC 
sample (4/9 cases), however, out of these four cases, three of them had a different TP53 
mutation present in the paired EAC sample (Barrett’s esophagus private mutations in Figure 
1c). Other previously reported putative EAC driver genes, such as EYS, ARID1A and 
ABCB1, were mutated less commonly (≤30%) and if mutated within a patient’s tissue (either 
Barrett’s esophagus or EAC), were seldom shared (21/73, (28.8%)) between the paired 
Barrett’s and EAC samples (Figure 1c).
In order to be sure that the poor overlap was not due to sampling bias we performed whole-
genome sequencing (WGS) on additional samples taken from 5/23 cases. These data showed 
a very similar degree of overlap to the paired Barrett’s and EAC data (Figure 1), regardless 
of whether you consider all samples together or any two samples from the Barrett’s 
esophagus compared with the EAC from the same patient (Supplementary Figure 1). Hence, 
taken together these data show that there is significant heterogeneity in the spectrum of 
mutations with surprisingly little overlap in the molecular genetics between EAC and 
adjacent Barrett’s esophagus.
Copy number increases as EAC develops
Although Barrett’s esophagus adjacent to EAC was found to be highly mutated, we 
observed a stark contrast between the copy number aberrations within the Barrett’s samples 
compared to the EAC samples (Figure 2a and b and Supplementary Figure 2). With the 
exception of two Barrett’s esophagus samples (from patients P3 and P21) both of which 
showed features in keeping with LGD, the Barrett’s esophagus samples, even those with 
HGD (patients P17 and P22), contained very few copy number changes, with the vast 
majority of their genomes being diploid (median percentage genome copy number 2 = 
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99.7% (range 62.8-100.0%)). This was significantly different from the EAC samples 
(Wilcoxon Signed Rank test, p<0.001), which showed a range of copy numbers including 
some highly amplified regions (15-20 copies), with a median percentage of the genome not 
diploid = 37.6% (range 2.1-87.8%).
The only common copy number change within the Barrett’s samples was 9p LOH which 
was present in 11/23 (48%) samples. The majority of EAC samples (16/23 (70%)) also had 
9p LOH. However, of the 11 Barrett’s samples with 9p LOH, only 7 also had the same 
alteration in their cancer sample. Within the EAC samples, when considering more focal 
copy number changes (i.e. less than half of the particular chromosome arm) we found 17 
commonly amplified (at least four copies) and 18 deleted regions that were present in at 
least 3/23 (13%) samples. The commonly amplified regions included previously reported 
amplified regions in EAC22, namely GATA4, KLF5, MYB, PRKCI, CCND1, FGF3, FGF4, 
FGF19 and VEGFA, some of which are potential therapeutic targets. The deleted regions 
included some known fragile sites (FHIT and WWOX) as well as some previously reported22 
and potentially interesting targets, namely A2BP1, CDKN2A, PDE4D, PTPRD and PARK2.
Mutational context is unchanged between Barrett’s and EAC
From the SNV overlap data we could infer the early SNVs (i.e. those present in both the 
paired Barrett’s and EAC samples) as well as the later events (i.e. SNVs unique to either the 
Barrett’s or the tumor samples). From these categorizations, we wanted to know whether the 
mutagenic stimulus was common between the early and the late events. The previously 
identified EAC mutational signature (A:T>C:G specifically at AAG trinucleotides)13,16 was 
similarly enriched in both the early and the late SNVs (both Barrett’s and EAC unique), 
(Figure 3a and b). There was a good correlation when comparing the mutational context 
between all the Barrett’s esophagus unique, the EAC unique and the common SNVs 
(average correlation = 0.83, 0.86 and 0.86, respectively), however, there appeared to be 
some difference between the early and the late SNVs, albeit small (6.9% variance in the 
second component), when using principal component analysis (Supplementary Figure 3a). 
This difference seems to be driven mainly by four different mutational contexts; A>C at 
CAC, C>G at CCG, A>T at CAC and C>G at TCA (Supplementary Figure 3b).
Spatial and temporal characterization of a Barrett’s segment
As we observed such heterogeneity in the genetic landscape between the paired Barrett’s 
and EAC samples, we sought to characterize, in precise detail, the Barrett’s esophagus 
segment from a single patient (AHM1051) in order to better understand the clonal evolution 
and how this relates to cancer development. To do this we studied multiple samples from a 
58-year-old male patient who displayed all the stages of the Barrett’s esophagus progression 
series; gastric metaplasia, intestinal metaplasia, LGD, HGD and intramucosal 
adenocarcinoma. Following a tertiary referral this patient underwent five endoscopies 
between May 2009 to March 2012, and samples were available across the full length of the 
patient’s 10 cm Barrett’s segment for this time period (outlined in Figure 4). This patient 
was also selected as he had previously swallowed a Cytosponge, which is a non-endoscopic 
cell sampling device that collects cells from the gastro-esophageal junction, the entire length 
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of the esophagus, as well as the oropharynx, providing an opportunity to assess the clonal 
architecture from a single sample, which may have clinical application.
Somatic SNVs (both coding (variant allele fraction (VAF)>0.08) and non-coding present at 
the highest VAFs within the different Barrett’s esophagus WGS libraries) were selected for 
targeted re-sequencing, with the expectation that these SNVs would define the clones 
present within this patient’s Barrett’s segment and could be assessed across a larger number 
of samples. Using a panel of 1,443 targets, sequencing was performed on 73 individual 
samples (Figure 4). We used a custom-made data browser to investigate this complex 
dataset (available with Supplementary Material). All but two of the 1,443 SNVs gave 
useable data with sufficient sequencing depth for the 73 samples with a median coverage of 
7,760× (IQR 6,015-10,100) for the samples and a median coverage of 6,504× (IQR 
3,285-10,940) for the 1,441 targets. 99.7% (1,437/1,441) of the selected SNVs were verified 
as real and somatic (VAF > 0.01).
Clonal heterogeneity within non-dysplastic Barrett’s
Within the patient’s sequenced Barrett’s samples, 22 biopsies showed no evidence of 
dysplasia. These samples were particularly interesting as we were interested to see the clonal 
ordering within low-risk Barrett’s epithelium that looked cytologically normal. Of these 
biopsies, one had gastric metaplasia and all the rest contained intestinal metaplasia. An 
initial analysis was performed using the Pearson correlation of the VAF values from the 
targeted amplicon sequencing. This method allowed us identify clones based on their overall 
mutation patterns, taking advantage of the large proportion of VAF that are affected by the 
extensive copy number changes in the EAC samples. Because it groups based on VAF 
patterns, this method is more resistant to variable clonality and purity. The analysis of these 
samples revealed six different groups and pairwise comparison of the samples (Figures 5a 
and b and Figure 6a) allowed us to derive the clonal hierarchy in the Barrett’s segment 
(Figure 5c).
Three SNVs, all occurring in non-coding regions and representing the most-recent common 
ancestor (chr4:33658353 T>C, chr13:88285478_A>C and chr18:11483749_A>C), were 
found in all six clones providing evidence for an initial clonal sweep of the patient’s 
Barrett’s segment. After this initial clonal sweep two very different clones arose, Clone 1 
and Clone 3 (Figure 5b and c) displaying many more genome-wide SNVs (Clone 1: 
819/1,437 assessed SNVs and Clone 3: 157/1,437 assessed SNVs). Clone 3 had 9p LOH, a 
common event observed in non-dysplastic Barrett’s esophagus and one that has been 
previously shown to impart selective advantage to Barrett’s esophagus cells7, however this 
clone did not appear to seed further clones within this patient’s Barrett’s segment (Figure 
5c). Unlike Clone 3, Clone 1 was able to seed a daughter clone, which we have called Clone 
2. Clone 2 contained 234 additional SNVs, compared to Clone 1 (colored in orange in 
Figure 5b), and subsequently this gave rise to two different clones, namely Clone 4 and 
Clone 6. Clone 4, containing 1,178/1,437 assessed SNVs, subsequently gave rise to an 
additional clone, Clone 5 (1,184/1,437 SNVs assessed as well as a large-scale deletion/
amplification on chromosome 15). Clone 6 (1,146/1,437 assessed SNVs), in addition to the 
93 extra SNVs compared to Clone 2, displayed a large number of copy number changes, 
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specifically large-scale deletions in chromosomes 5, 11, 13 and 18, as evidenced by the 
jagged appearance of the VAF plots in Figure 5a and supported by the WGS data 
(Supplementary Figure 4). This is especially interesting as all of the three samples that are 
classified as Clone 6 were assigned a histopathological diagnosis of non-dysplastic Barrett’s 
esophagus although they contain a large number of somatic mutations and copy number 
changes. More information on how the clonal hierarchy was derived can be found in online 
methods. It should be noted that whether or not the sample sequenced was fresh-frozen or 
paraffin-embedded did not lead to any systematic bias that affected the clonal assignments.
Dysplasia can develop from multiple different clones
In addition to multiple regions of Barrett’s esophagus with no dysplasia, patient AHM1051 
has multiple areas with cellular abnormalities which were graded according to the degree of 
dysplasia by consensus review by two expert gastrointestinal pathologists. These samples 
allowed us to assess the clonal architecture within the Barrett’s esophagus progression 
sequence. Clone 6 (Figure 5a and Supplementary Figure 3) displayed the highest number of 
copy number changes and would be the obvious culprit for seeding HGD. However, 
interestingly, Clones 2, 3 and 6 were all found to give rise to HGD (Figure 6a, b and c). 
Similarly clones 2, 3, 4 and 6 all appeared to give rise to LGD. Clones 1 and 5 were the 
exceptions for LGD; however, as there are few samples available from these two clones, this 
may be a result of sampling bias.
Stability of the Barrett’s esophagus segment over time
Taken together, these data demonstrate a genetically stable clonal pattern within this 
patient’s 10-cm Barrett’s segment. All six identified clones were present in 2009, the year 
that this patient was diagnosed as having Barrett’s esophagus with dysplasia. Almost three 
years later, the same six clones can be identified (Figure 6c). The only alteration to the 
Barrett’s esophagus segment appears to be as a result of this patient’s clinically ineffective 
endoscopic treatment which resulted in the shrinking of Clone 3 (only partially visible in 
one biopsy post-treatment). This decrease in Clone 3 is further evident using a non-
endoscopic, cell sampling device, the Cytosponge. Amplicon sequencing of cells collected 
using the Cytosponge taken after endoscopic treatment (March 2012), showed no evidence 
of Clone 3 (Figure 6d) suggesting that this clone had substantially shrunk in response to 
endoscopic therapy. However, SNVs defining clones 1, 2, 4, 5 and 6 were all present within 
the Cytosponge sample and clone 6 was the most abundant in keeping with the large size of 
this clone ascertained form the biopsy data (Figure 6d). This suggests that the Cytosponge 
could simultaneously sample all five clones present within the patient’s Barrett’s segment 
and provide some indication of relative clone size.
Given the pathogenic importance of TP53, in a more targeted approach we also mapped 
mutations at this locus within this patient’s Barrett’s segment. TP53 sequencing on the 
Cytosponge sample13, identified a dominant TP53 mutation (chr17:7577538 C>T) which 
was also identified in the WGS. This particular TP53 mutation established itself in Clone 2 
(VAF between 0.28 – 0.56) and was therefore also present in all the daughter clones (i.e. 
Clones 4, 5 and 6) (shown by slanted white lines in Figure 6c), however, with a much higher 
VAF in Clone 6 (between 41-73%), probably due to LOH. The presence of a TP53 mutation 
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in non-dysplastic Barrett’s esophagus from a patient with early cancer is similar to that seen 
in the WGS data which showed that 4/17 (23.5%) non-dysplastic Barrett’s samples taken 
adjacent to EAC contained TP53 mutations. These data from patients who have progressed 
to cancer should not be confused with studies that look at the TP53 mutation prevalence in 
non-dysplastic Barrett’s esophagus from patients who never progress to dysplasia and/or 
EAC13,23,24 .
Discussion
In summary, the application of powerful sequencing technology to cases of Barrett’s 
associated carcinogenesis has led to new insights about the history of the disease. Firstly, 
there are numerous somatic point mutations as well as small insertion and deletions which 
occur in all pathological stages of the disease progression. The specific SNVs generally 
overlap poorly between paired Barrett’s and EAC samples, however, the mutational context 
of these SNVs is mostly common between the ends of the disease spectrum (non-dysplastic 
Barrett’s esophagus and EAC) suggesting exposure to common mutagens throughout the 
progression sequence. Although the mutational context is consistent along the progression 
sequence, there is a marked increase in the copy number changes in EAC, which is rarely 
seen in Barrett’s epithelium. From a clinical perspective, the histopathological assessment of 
dysplasia appears to be a poor reflection of the molecular disarray within the Barrett’s 
epithelium as the same aberrant genetic profile was seen in both dysplastic and non-
dysplastic Barrett’s tissue.
The variation in the overlap between the paired Barrett’s and EAC samples in this study, 
especially the high proportion of patients’ samples that showed such heterogeneity (13/23 
Barrett’s-EAC pairs with <20% overlap), was surprising. However, these data do 
demonstrate how much the Barrett’s segment has evolved since seeding the tumor giving an 
indication as to the long natural history of the condition. One way to capture this genetic 
heterogeneity in patients with a patent lumen is using the non-biased Cytosponge which we 
have shown can sample all five remaining clones in patient AHM1051’s Barrett’s esophagus 
segment after endoscopic therapy. This is a proof-of principle experiment and further work 
is required to demonstrate the clinical utility of this sampling approach for detecting 
mutations representative of the entire Barrett’s esophagus segment.
The in-depth study of the Barrett’s esophagus segment of patient AHM1051 led to a detailed 
map of the clonal ordering and heterogeneity within a 10-cm Barrett’s segment. All six 
clones identified in this Barrett’s esophagus segment contain multiple SNVs and have 
varying abilities to seed further daughter clones. Furthermore, not all of the six clones span 
the whole length of the Barrett’s esophagus segment, but some appear to remain more 
localized. The clonal pattern present in this patient has aspects of both models that have 
previously been proposed for the clonal evolution of Barrett’s esophagus6,7. There is 
evidence of a common ancestor prior to branched evolution within the patient’s Barrett’s 
segment, indicated by the three non-coding, common mutations present in all Barrett’s 
esophagus samples. This is also supported by the common SNVs identified between the 23 
paired Barrett’s esophagus and EAC samples. However there is also evidence for the 
emergence of distinct clones, such as Clone 1 and 3, neither of which were able to sweep 
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across the whole Barrett’s segment. Furthermore, deep sequencing of individual Barrett’s 
esophagus biopsies has allowed the identification of multiple clones within the same biopsy, 
demonstrating that this approach is sufficient to identify the clonal heterogeneity within 
Barrett’s esophagus without requiring further microdissection.
This study is only one step in further understanding clonal evolution and heterogeneity in 
Barrett’s esophagus. The holy grail is still to be able to predict which patients will develop 
dysplasia and ultimately cancer. Approaches, such as the one used here, have the ability to 
further improve our understanding of the clonal structure within Barrett’s esophagus before 
and after the development of dysplasia, with the hope of being able to predict which patients 
will progress to cancer. Li et al25 recently reported that Barrett’s esophagus patients who do 
not progress to cancer have stable genomes, whereas patients who progressed to cancer had 
unstable and diverse genomes which evolved at least four years before developing a cancer. 
However, our data suggest a more complex situation since HGD can arise from multiple 
different clones, some of which appear to have very few copy number aberrations. The 
clinical implication of these findings is that when endoscopic therapies, such as mucosal 
resection or ablation, are undertaken there is a need to treat the whole Barrett’s esophagus 
segment to ensure that no residual Barrett’s epithelium remains. This is important as meta-
analysis of 18 studies demonstrated that Barrett’s esophagus with intestinal metaplasia was 
still present in 22% of individuals (95% confidence interval: 14-30%) who were treated with 
radiofrequency ablation26.
In conclusion, this study has shed more light on the similarities and differences in the 
genetic aberrations in the progression from Barrett’s esophagus to EAC. In the future it will 
be important to integrate transcriptomic and epigenetic data with genome-wide DNA 
sequence in patients who span the disease spectrum. This approach, which incorporates state 
of the art technology on fresh and archival specimens, paves the way for further studies in 
other tissue types aiming to chart the progress from intra-epithelial to invasive cancer.
Online methods
Patients, clinical material and consent
This study was approved by the Institutional Ethics Committees (REC Ns 07/H0305/52, 10/
H0305/1 and 10/H0308/71) and all patients gave individual informed consent. Patients with 
EAC were recruited prospectively at six different centers (Addenbrookes Hospital, 
Cambridge, Royal Surrey County Hospital, Guildford, St Thomas Hospital, London, 
Gloucester Royal Hospital, Gloucester, Edinburgh Royal Infirmary, Edinburgh and Salford 
Royal Infirmary, Manchester) and samples (both cancer and Barrett’s esophagus) were 
obtained at the same time either from surgical resection, endoscopic ultrasound or 
endoscopic mucosal resection. Blood (for 22/23 EAC patients) or frozen normal squamous 
esophageal samples at least 5cm distant from the tumor (for 1/23 patients), were used as a 
germline reference. For the Barrett’s esophagus patient (AHM1051) who was studied in 
detail, a frozen duodenum sample was used as the germline control. Tissue samples were 
either snap-frozen in liquid nitrogen immediately after collection and stored at −80°C or 
formalin-fixed and paraffin embedded (FFPE) as per the usual clinical protocol. Prior to 
DNA extraction, one section was cut from each esophageal tissue sample and H&E staining 
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was performed to assess the exact histopathology for every individual sample. EAC samples 
were deemed suitable for DNA extraction only after consensus review by two expert 
gastrointestinal pathologists confirmed the tumor cellularity to be ≥70%. Where blood was 
not available for the germline reference the same review process was applied to the normal 
esophageal samples to ensure that only squamous epithelium was present. Barrett’s 
esophagus samples, both frozen and FFPE, were reviewed by two expert gastrointestinal 
pathologist (M O’D and SM) to identify any dysplasia or cancer cells. For the whole-
genome sequencing, Barrett’s esophagus samples with any evidence of cancer cells or 
cancer samples with any evidence of Barrett’s esophagus, were excluded.
DNA extraction from clinical material
For the frozen normal, Barrett’s esophagus and EAC samples, DNA was extracted from the 
tissue using either the DNeasy kit (Qiagen) or the AllPrep DNA/RNA Mini Kit (Qiagen), 
according to the manufacturer’s instructions. DNA was extracted from blood samples using 
the Nucleon™ Genomic Extraction kit (Gen-Probe,) according to the manufacturer’s 
instructions. For the Barrett’s esophagus FFPE biopsy samples, genomic DNA was extracted 
from the rest of the diagnostic biopsy and each diagnostic biopsy was extracted separately. 
For the Cytosponge sample, genomic DNA was extracted from 8 × 10 μm sections of the 
processed Cytosponge FFPE clot. The FFPE samples were extracted using Deparaffinization 
Buffer (Qiagen) and the QIAamp FFPE DNA Tissue Kit (Qiagen). The protocol was 
followed as described by the manufacturer with the exception that samples were incubated at 
56°C for 24 hours instead of the described 1 hour, and 10 μl of extra Proteinase K was added 
to the samples roughly half way through the 24 hour incubation. For all sample types the 
DNA was quantified using the Qubit™ dsDNA BR or HS Assay Kits (Life Technologies).
Whole-genome sequencing analysis
For the patients with EAC; a normal, a Barrett’s esophagus and a cancer sample were 
sequenced for each of the 23 patients. For 5/23 patients, additional Barrett’s esophagus and 
EAC samples were also sequenced. For the Barrett’s esophagus patient, AHM1051, 13 
samples were sequenced of which 10 were from fresh-frozen biopsies and 3 were from 
FFPE diagnostic biopsies. The 13 samples included two normal esophageal squamous, one 
duodenum, three Barrett’s esophagus with intestinal metaplasia, two Barrett’s esophagus 
with gastric metaplasia, two Barrett’s esophagus with LGD, two Barrett’s esophagus with 
HGD, and one with intramucosal adenocarcinoma. The 13 samples were collected between 
May 2009 and March 2012.
For all fresh-frozen samples, libraries were constructed with ~300bp insert length. For all 
FFPE derived samples, library preparation followed a modified TruSeq PCR Free protocol 
designed to retain more fragments of low molecular weight an abundance of which are often 
present in FFPE derived DNA as a result of degradation of the sample. Whole genome 
sequencing (WGS) was performed on the Illumina HiSeq2000 instrument. We generated 
100 bp paired-end sequence reads using v3 clustering and sequencing chemistry. Alignment 
to human GRCh37.1 and quality control was performed using the Illumina CASAVA v1.8 
pipeline for the AHM1051patient WGS data and using ISAAC28 for all samples of the 
patients with EAC. Identification of somatic single nucleotide variants (SNVs) and somatic 
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small indels (<50bp) was performed by Strelka29 in the 12 Barrett’s esophagus samples 
from patient AHM1051 using the duodenum sample as the matching normal sample and in 
both cancer and Barrett’s esophagus samples using the matched normal for the patients with 
EAC.
The overlap of SNV calls between a matching Barrett’s esophagus and EAC sample was 
calculated as: at the union of SNV positions, the base counts for variant and reference allele 
were retrieved. Positions that did not achieve at least 18× coverage in both samples, that 
have more than 1500× coverage or that have more than 10 reads filtered out because of poor 
alignment score in either sample were discarded from the following counts. Positions were 
considered in the intersection (overlap) if there were high quality reads in one sample for a 
mutation to be called with high confidence. In this case we would look at the other paired 
sample to determine if there was any evidence to support the somatic variant in that sample. 
Since it was highly unlikely that the exact same base pair change would occur in another 
sample from that patient by chance, a single read was considered to be sufficient supporting 
the variant allele; SNVs were considered unique in Barrett’s esophagus or EAC if the 
corresponding EAC or Barrett’s esophagus sample contained only reference bases covering 
the position. The unique SNVs were further separated into two categories depending on 
whether or not they fell in regions of LOH in the paired sample, as one cannot tell if those 
SNVs are truly unique to the sample or have been lost in the other sample. Half of the 
coding SNVs (47/89) as well as all of the indels (9/9) shown in Figure 1c were manually 
reviewed to ensure that the observations were robust and not a result of any analysis artefact. 
All of the inspected 47 SNVs and 9 indels were found to be real and somatic. 101 SNVs (of 
which 49 were classed as Barrett’s esophagus unique, 41 EAC unique and 11 common 
between the Barrett’s esophagus and the EAC sample) from Patient 3, representing a patient 
with poor overlap between the paired Barrett’s esophagus and EAC samples, were manually 
reviewed. 99/101 (98%) were confirmed to be real and somatic with the other two being 
classed as inconclusive.
The mutational context of SNVs was calculated as in Nik-Zainal et al.27 for each of the 
three subsets of SNVs per patient: (i) unique to Barrett’s esophagus not in EAC LOH, (ii) 
unique to EAC not in Barrett’s esophagus LOH, and (iii) common to Barrett’s esophagus 
and EAC. Pairwise correlations for each of the comparisons were performed and then 
averaged to give an average correlation value per comparison.
Copy number and loss of heterozygosity analysis
A two-step workflow was used for the detection of copy number and LOH changes (data not 
shown). First, GC-normalized coverage and B-allele ratios were derived from tumour and 
normal samples and jointly segmented using an unbalanced Haar wavelet transform. Next, 
given the location of change points in the genome, a least-squares model was applied to 
derive purity and ploidy that were used to assign a copy number to each segment. For this 
last step, the observed coverage, germline and somatic B-allele ratios were compared with 
the expected ones for each copy number, purity and ploidy combination to identify the 
model with the smallest least-squares value. Since this method is unpublished we also ran 
CNAnorm for case P12 EAC and demonstrated the same results30.
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Amplicon sequencing material and analysis for patient AHM1051
In order to assess any clonal heterogeneity within patient AHM1051’s Barrett’s esophagus 
segment, SNVs with the highest variant allele fraction (VAF) in each Barrett’s esophagus 
WGS library (all with a VAF >0.25), as well as all coding SNVs with a VAF > 0.08, were 
selected for amplicon sequencing. This resulted in the selection of 1,801 SNVs which were 
deemed to have the potential to define clones within this patient’s Barrett’s esophagus 
segment. After running Illumina’s Design Studio software for the TruSeq Custom Amplicon 
(TSCA) Protocol, 1,443 loci were deemed fit for the TSCA Protocol (Illumina).
Targeted sequencing, using the TSCA protocol followed by high throughput sequencing on 
the HiSeq2000, was performed on 73 individual samples (70 Barrett’s esophagus samples 
and 3 normal samples) including 10 of the original 13 samples used for WGS. Of the 73 
samples, 64 were FFPE and 9 were fresh-frozen. For three of the original Barrett’s 
esophagus WGS samples there was not enough material remaining. The 70 Barrett’s 
esophagus samples represented the whole length of the Barrett’s esophagus segment and 
were taken from five different endoscopy visits, three which were before any endoscopic 
treatment (05/2009, 10/2009, 02/2010) and two which were post treatment (03/2011, 
03/2012); endoscopic mucosal resection performed on the 22/04/2010 and radiofrequency 
ablation performed on the 8/12/2010. Three normal control samples (the same as used for 
WGS) were also included in the amplicon sequencing experiment. The TSCA protocol was 
performed as described by the manufacturer followed by data analysis using ISIS 2.4 
Custom Amplicon Workflow for processing the alignments. For downstream analysis the 
read depth and VAF of each target base was extracted for all samples. Individual positions 
with read depth ≤20 were considered as zero depth (ie. no VAF value at those positions).
Visualization of the targeted amplicon-sequencing data
A custom bioinformatics tool was designed and constructed using the JavaScript library 
d3.js, to allow interrogation and exploration of the TSCA data. The tool, available in 
supplementary data, loads 3 data files: the sample metadata (date of sampling, location down 
the esophagus, histology report, DNA concentration and TSCA average depth), the 
sequencing metadata (genomic location, base change and annotation, including gene and 
consequence when relevant) and the VAF values for all targets in all samples (null values 
were converted to 0). The tool allows three main interactive explorations of the data: (i) 
visualization of TSCA data for individually selected samples in a Manhattan-like plot where 
the Y-axis displays the VAF values of the targets within each given sample ordered on the 
X-axis according to genomic coordinate; (ii) a pairwise scatterplot of VAF values between 
two selected samples and (iii) a hierarchical tree of the samples. The tree display is dynamic 
and allows the user to remove samples and/or targets and to choose between five distance 
metrics between samples.
The five distance metrics (binary, Euclidean, Manhattan, Max and Pearson) are described in 
the help page of the tool. All analysis results were given using the Pearson metric
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where D(A,B) is the Pearson distance between samples A and B and  is the variant read 
fraction of mutation i in sample A.
A distance matrix is generated by calculating all pairwise distances between samples. This 
distance matrix is then used to generate the tree using hierarchical clustering using the 
complete methodology for linkage of the nodes.
Determining the clonal hierarchy within the Barrett’s segment of patient AHM1051
Clone 3 is distinctly different from the five other identified clones and only shares 3 SNVs 
in common with the other five clones. Clone 1 is the oldest clone out of the other five clones 
and contains 819/1,437 assessed SNVs. Clone 2 then arose from Clone 1 as Clone 1 and 2 
share the same 819 SNVs and in addition Clone 2 contains 234 SNVs (Clone 2 has a total of 
1,053/1,437 SNVs assessed). Clone 4 must have arisen from Clone 2 as it contains the same 
1,053 SNVs as Clones 2 as well as 125 more SNVs which are not present in either Clone 1 
or 2 (Clone 4 has a total of 1,178/1,437 SNVs assessed). Clone 5 then arose from Clone 4 as 
it contains the same 1,178 SNVs as Clone 4 as well as 6 additional SNVs and a large scale 
deletion in chromosome 15 (evidenced by the increased VAF in the VAF plot in Figure 5a). 
Clone 6 must have arisen from Clone 2 as Clones 4 and 5 do not share all their SNVs with 
Clone 6. Clone 1 and 2 do share the majority of its SNVs with Clone 6 (with the exception 
of some SNVs which are probably lost through copy number changes present in Clone 6). 
Clone 6 contains an additional 93 SNVs compared to Clone 2, as well as multiple copy 
number changes in chromosomes 5, 11, 13 and 18.
Statistical analysis
The Mann-Whitney test was used to compare continuous variables between groups and a 
Fisher’s Exact Test was used to compare counts between categorical variables. All reported 
p values were two sided.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Paired Barrett’s and EAC samples have a varied overlap
a) Scatter plot comparing the mutation rate between paired Barrett’s and EAC samples. 
Light blue dots indicate Barrett’s samples with some degree of dysplasia present. b) 
Diagram showing percentage overlap between SNVs in paired Barrett’s and EAC samples, 
including highlighting SNVs that lie in areas of LOH in the reciprocal sample. Barrett’s 
unique SNVs that lie in an area of LOH in the paired EAC sample are shown in light pink 
and EAC unique SNVs that lie in a region of LOH in the paired Barrett’s sample are shown 
in white. Samples are ranked according to their degree of overlap, from poor to good. 
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Scatter plots illustrating an example of a poor overlap (patient P1), a fair overlap (patient 
P13) and a good overlap (patient P21) are shown. c) Bar graph showing genes that were 
found to be recurrently mutated in previous EAC sequencing studies13,16 and are mutated in 
at least two patients in our Barrett’s-EAC cohort (SNVs or indels). For each gene of interest 
the data for the Barrett’s samples are in the bar labelled “B” and for cancer samples in the 
bar labelled “C”. Mutations that are common to both paired Barrett’s and EAC samples 
(shown in teal), as well as mutations that are Barrett’s unique (dark pink) or EAC unique 
(dark grey) are shown. Also shown are mutations in the same gene that have a different base 
pair change between paired Barrett’s and EAC samples (called “private mutations”).
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Figure 2. EAC samples display multiple copy number changes compared to paired Barrett’s 
esophagus samples
a) Graphs showing the percentage of the genome at different copy number states for each 
patient (P) in turn (P1-23) for their paired Barrett’s esophagus (left hand graph) and EAC 
samples (right hand graph). CN0 = copy number 0, CN1 = copy number 1, CN2 = copy 
number 2, CN3 = copy number 3, CN4 = copy number 4, CN5+ = at least copy number 5. b) 
Stacked mountain plots summarizing copy number variation within all of the 23 Barrett’s 
esophagus and EAC samples. Gains of at least two copies on top of the normal copy number 
in that region are illustrated by yellow-orange-red mountains and deletions are represented 
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by green-blue valleys. The height or depth of the mountain or valley indicates the summed 
copy number status across all patients for that region. The colors represent different samples 
so that the higher the number of different colors in a region, the higher the number of 
samples that display that copy number change.
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Figure 3. The mutational context is similar in both early and late SNVs
a) Heat map showing the log-transformed values representing the fraction of each mutation 
type at each trinucleotide mutation context corrected for the frequency of each trinucleotide 
in the reference genome, as described in Nik-Zainal et al27. The mutational contexts were 
calculated separately for the three subsets of SNVs per patient, i.e. 1. Barrett’s unique and 
not in EAC LOH, 2. common to Barrett’s esophagus and EAC, and 3. EAC unique and not 
in Barrett’s esophagus LOH. b) Mutational context plotted as a dot plot showing the 
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enrichment of the trinucleotide mutational context information for every possible option for 
all 23 paired Barrett’s esophagus and EAC samples.
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Figure 4. Summary of the samples sequenced for patient AHM1051
Ten Barrett’s esophagus samples (depicted by crosses on patient AHM1051’s Barrett’s 
segment) representing all stages along the progression sequence from Barrett’s esophagus 
with no dysplasia to intramucosal adenocarcinoma, as well as two normal esophageal 
squamous (NE) and one duodenum (D2) sample were sequenced (whole-genome 
sequencing, WGS). From the WGS data, 1,437 SNVs were assessed on additional FFPE 
samples taken from multiple different endoscopies across the full length of the 10cm 
Barrett’s esophagus segment between May 2009 and March 2012. The biopsy samples 
selected for amplicon sequencing are shown using black dots (positions of the biopsies along 
the x-axis are for illustration only and hold no extra information). One Cytosponge sample 
taken in March 2012 was also included in the amplicon sequencing.
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Figure 5. Six distinct clones are present within patient AHM1051’s non-dysplastic Barrett’s 
esophagus
a) Variant allele fraction (VAF) plot representing an example sample of the six distinct 
clones. The 1,437 assessed SNVs are represented by dots within the chart. The SNVs are 
ordered on the x-axis according to their genomic location (from chr1 to sex chromosomes). 
The y-axis represents the VAF for each mutation for that sample. The blue dots represent 
intergenic or intronic SNVs and the red dots represent coding SNVs. b) Scatter plots 
showing the correlation between two different representative samples within the same clone 
as well as compared to two different samples from every other clone. The sample names 
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(e.g. S6 (sample 6)) are given under the different clone headings. Each dot within the scatter 
plot represents one of the 1,437 assessed SNVs and the dots are coloured according to the 
different clones the SNVs belong to. The r value represents the Pearson correlation. c) 
Diagram representing the clonal ordering within patient AHM1051’s Barrett’s esophagus 
segment. The numbers in brackets represent the number of SNVs (out of a total of 1,437 that 
were assessed) that are present in each of the clones.
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Figure 6. Multiple different clones can give rise to dysplasia
a) Hierarchical tree showing all samples processed for amplicon re-sequencing. Within the 
tree, samples are paired according to their Pearson correlation score. The distance between 
pairs is represented by the horizontal distance between the pair and their parent node. There 
is no information embedded in the vertical distance of this tree. The colors of the boxes 
represent the histopathological grade for each of the Barrett’s esophagus samples. The width 
of the boxes is proportional to the number of SNVs with VAF>0.01 in each sample. The 
clones represented by the six different branches are noted. b) VAF plots as described in 
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Figure 5a showing examples of samples that contain ≥40% high grade dysplasia (as 
determined by the average between two expert upper gastrointestinal pathologists) within 
the sample and grouped according to which clones they represent. The number at the top of 
each graph indicates the percentage of high grade dysplasia in that specific sample, as 
assessed by two expert gastrointestinal pathologists. c) Illustration depicting the clonal 
arrangement in patient AHM1051’s Barrett’s esophagus segment before (2009-2010) and 
after (2011-2012) endoscopic treatment. The region corresponding to high grade dysplasia, 
before and after treatment, is shown using a dashed line. The clones containing the widely-
spread TP53 mutation are indicated by thin, slanted, white lines. d) Scatter plots indicating 
the correlation between SNVs identified in the DNA from cells collected using the 
Cytosponge compared with the six different clones. The r value represents the Pearson 
correlation.
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